Virological factors associated with outcome of dual maraviroc/raltegravir therapy (ANRS-157 trial)

ROCnRAL ANRS-157 was a single-arm study designed to evaluate a switch to a maraviroc (300 mg twice a day) plus raltegravir (400 mg twice a day) regimen in virologically suppressed HIV-1-infected patients (ClinicalTrials.gov: NCT01420523). The aim of this work was to investigate the factors associate...

Full description

Saved in:
Bibliographic Details
Published in:Journal of antimicrobial chemotherapy 2015-12, Vol.70 (12), p.3339-3344
Main Authors: Soulié, Cathia, Assoumou, Lambert, Darty, Mélanie, Rodriguez, Christophe, Donati, Flora, Sayon, Sophie, Peytavin, Gilles, Valantin, Marc-Antoine, Caby, Fabienne, Schneider, Luminita, Canestri, Ana, Costagliola, Dominique, Katlama, Christine, Calvez, Vincent, Marcelin, Anne-Geneviève
Format: Article
Language:English
Subjects:
Anti-HIV Agents - therapeutic use
Antiretroviral drugs
Clinical outcomes
Cyclohexanes - therapeutic use
HIV
HIV Infections - drug therapy
HIV Infections - virology
HIV-1 - isolation & purification
Human immunodeficiency virus
Raltegravir Potassium - therapeutic use
Risk Factors
Treatment Failure
Triazoles - therapeutic use
Viral Load
Virology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:ROCnRAL ANRS-157 was a single-arm study designed to evaluate a switch to a maraviroc (300 mg twice a day) plus raltegravir (400 mg twice a day) regimen in virologically suppressed HIV-1-infected patients (ClinicalTrials.gov: NCT01420523). The aim of this work was to investigate the factors associated with virological failure (VF) (5/44 patients) or virological rebound defined as one viral load (VL) >50 copies/mL or VL >1 copy/mL. At baseline (BL), ultradeep sequencing (UDS) of DNA gp120 V3 and integrase regions and quantification of HIV DNA were performed in PBMCs. Tropism, VL, BL ultrasensitive HIV RNA VL, BL HIV DNA VL, subtype, age, ethnicity, transmission group, AIDS status, nadir CD4 and BL CD4 cell count, time since HIV diagnosis, duration of ART and suppressed viraemia, VL zenith, CD4/CD8 ratio and BL CD8 cell count were investigated as potential factors associated with virological rebound. The proportion of patients with VL
ISSN:0305-7453
1460-2091
DOI:10.1093/jac/dkv280